Chemoradiation with Capecitabine and Mitomycin-C for Stage I-III Anal Squamous Cell Carcinoma-Juniper Publishers

Juniper Publishers-Open Access Journal of Cancer Therapy and Oncology

Chemoradiation with Capecitabine and Mitomycin-C for Stage I-III Anal Squamous Cell Carcinoma

Authored by Hagen Kennecke

Carcinoma of the anal canal is relatively uncommon, yet incidence is on the rise. The accepted current standard regimen for patients with stage I-III squamous cell carcinoma (SCC) of the anal canal is radiotherapy (50.4 Gy) with concurrent infusional 5-fluorouracil (5-FU) (825 mg/m2 per oral bi-daily) administered on radiation days during weeks one and five and mytomycin C (MMC) (12 mg/m2) administered on week one. This study describes the efficacy and safety of substituting oral capecitabine (Cap) for the infusional 5-FU and compares the planned versus delivered therapy, and describes treatment-related patient toxicities and early outcomes in a population-based setting.

To Read More..PHP in  Cancer Therapy & Oncology International Journal in Juniper Publishers